Reviewing ClearPoint Neuro (NASDAQ:CLPT) and Bluejay Diagnostics (NASDAQ:BJDX)

Bluejay Diagnostics (NASDAQ:BJDX) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Insider & Institutional Ownership

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Bluejay Diagnostics and ClearPoint Neuro, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	0	0	0	0	0.00
ClearPoint Neuro	0	0	3	0	3.00

ClearPoint Neuro has a consensus price target of $19.6667, suggesting a potential upside of 70.27%. Given ClearPoint Neuro’s stronger consensus rating and higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Bluejay Diagnostics.

Profitability

This table compares Bluejay Diagnostics and ClearPoint Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-362.07%	-299.10%
ClearPoint Neuro	-66.15%	-94.44%	-51.58%

Valuation & Earnings

This table compares Bluejay Diagnostics and ClearPoint Neuro”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	$250,000.00	8.11	-$7.72 million	($125.15)	-0.01
ClearPoint Neuro	$31.39 million	10.46	-$18.91 million	($0.81)	-14.26

Bluejay Diagnostics has higher earnings, but lower revenue than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Bluejay Diagnostics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Summary

ClearPoint Neuro beats Bluejay Diagnostics on 11 of the 14 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.